1-8 of 8
cobra venoms
Close
Sort by
Journal Articles

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Alex Vasuthasawat, BS, MS, Reiko E Yamada, Kham R Trinh, Neiki Rokni, Sherie L Morrison, PhD, John M. Timmerman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1575.
https://doi.org/10.1182/blood-2019-131890
Published: 2019
Journal Articles

In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice

Yuanbin Song, MD, Liang Shan, PhD, Rana Gbyli, MS, Wei Liu, PhD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Ashley Qin, Amisha Patel, MS, Yimeng Gao, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, David Urbonas, Jonathan Alderman, PhD, Stephanie Halene, MD, Richard Flavell, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 338.
https://doi.org/10.1182/blood-2019-130701
Published: 2019
Journal Articles

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Jia Yu, Xuan Yuan, MD MSc, Kang Zhou, Daniel White, Samuel A. Merrill, MD PhD, Robert A. Brodsky, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3748.
https://doi.org/10.1182/blood-2018-99-119445
Published: 2018
Journal Articles

The Effects of the Spleen Tyrosine Kinase Inhibitor, Fostamatinib, on an Immune Thrombocytopenia Mouse Model

Gulsum Emel Pamuk, Professor Dr., MD, Mehmet Sevki Uyanik, Hematology Fellow, MD, Turan Karaca, Professor, PhD, Demirtas Selim, Research Assistant, PhD, Muzaffer Demir, Professor Dr., MD, Omer Nuri Pamuk, Professor Dr., MD
Journal: Blood
Blood (2014) 124 (21): 2782.
https://doi.org/10.1182/blood.V124.21.2782.2782
Published: 2014
Journal Articles

Complement Enhances Foxp3+ T Regulatory Cell Induction by B Cell Lymphoma

Suresh Veeramani, DVM, PhD, Chris Dahle, MS, George Weiner, MD
Journal: Blood
Blood (2010) 116 (21): 5176.
https://doi.org/10.1182/blood.V116.21.5176.5176
Published: 2010
Journal Articles

Depletion of the C3 Component of Complement Enhances the Ability of Rituximab-Coated Target Cells to Activate Human NK Cells and Improves the Efficacy of Monoclonal Antibody Therapy in An in Vivo Model

Siao- Yi Wang, Jeffrey Cagley, David Fritzinger, Carl-Wilhelm Vogel, William St. John, George J Weiner
Journal: Blood
Blood (2008) 112 (11): 3620.
https://doi.org/10.1182/blood.V112.11.3620.3620
Published: 2008
Journal Articles

Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice.

Stéphane Dalle, Lina Reslan, Stéphanie Brunet Manquat, Franck Herting, Christian Klein, Pablo Umana, Charles Dumontet
Journal: Blood
Blood (2008) 112 (11): 1585.
https://doi.org/10.1182/blood.V112.11.1585.1585
Published: 2008
Journal Articles

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

Mark S. Cragg, Martin J. Glennie
Journal: Blood
Blood (2004) 103 (7): 2738–2743.
https://doi.org/10.1182/blood-2003-06-2031
Published: 2004